KANAPH Therapeutics uses a genomics‑driven platform to discover disease signatures and translate them into next‑generation therapeutics for solid‑tumor oncology and ocular diseases. The company integrates human genome analysis with protein engineering to create bispecific antibodies, synthetic small‑molecule pipelines, and advanced ADCs featuring hydrophilic linkers and customizable payloads, delivering highly selective candidates from target validation through preclinical and early clinical stages.
Funding
$17.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatment options for many solid tumors and ocular diseases are limited by low specificity, resistance mechanisms, and inadequate delivery of therapeutic payloads, leading to suboptimal efficacy and safety.
Solution
Kanaph Therapeutics leverages a genomics-driven discovery platform to identify disease signatures and translate them into next‑generation therapeutics. The company integrates human genome and bio‑information analysis to pinpoint novel targets, then applies protein engineering to create bispecific antibodies, synthetic small‑molecule pipelines, and advanced antibody‑drug conjugate (ADC) technologies. Their ADC platform uses hydrophilic linkers and diverse payload mechanisms to overcome the pharmacokinetic and toxicity challenges of conventional ADCs. By combining these modalities, Kanaph aims to deliver highly selective, mechanism‑based candidates for oncology and ophthalmology indications, progressing them from target validation through preclinical and early clinical stages.
Target Audience
Primary customers are pharmaceutical companies and biotech partners seeking novel, mechanism‑driven therapeutic candidates for solid tumor oncology and retinal disease programs.
Features
- Genomics‑based target discovery pipeline that correlates patient disease signatures with actionable molecular candidates
- Bispecific antibody design and production platform optimized for high expression and manufacturability
- Integrated small‑molecule discovery system linking compound design, in‑silico evaluation, and library generation
- ADC technology featuring hydrophilic linkers and customizable payloads to improve solubility and therapeutic index
- Portfolio of preclinical candidates (e.g., FAP‑targeted IL‑12 cytokine, dual Fc fusion for wet AMD, EP2/EP4 dual inhibitor, SHP2 allosteric inhibitor, SOS1 inhibitor, anti‑cMET/EGFR bispecific ADC) addressing solid tumors and ocular diseases
- End‑to‑end development workflow from genomic analysis through preclinical validation and IND‑enabling studies